2026-05-20T03:47:20Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/233762024-11-28T17:24:29Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16960col_20.500.12105_16967col_20.500.12105_16970
Repisalud
author
Rey-Bua, Beatriz
author
Cabrero, Mónica
author
Bento, Leyre
author
Montoro, Juan
author
Bastos-Oreiro, Mariana
author
Parody, Rocio
author
Yanez, Lucrecia
author
Lopez-Godino, Oriana
author
Zanabili, Joud
author
Herrera, Pilar
author
Gutierrez, Gonzalo
author
Perez, Ariadna
author
Piñana, Jose L
author
Novelli, Silvana
author
Cortés, María
author
Sureda, Ana Maria
author
Caballero, Dolores
author
García-Sancho, Alejandro Martín
2024-10-04T13:16:22Z
2024-10-04T13:16:22Z
2022-11-18
Rey-Búa B, Cabrero M, Bento L, Montoro J, Bastos-Oreiro M, Parody R, et al. Allogeneic Hematopoietic Stem Cell Transplantation in Transformed Follicular Lymphoma (tFL): Results of a Retrospective Multicenter Study from GELTAMO/GETH-TC Spanish Groups. Cancers (Basel). 2022 Nov 18;14(22):5670.
10.3390/cancers14225670
2072-6694
Cancers
http://hdl.handle.net/20.500.13003/18685
36428762
L2020231296
2-s2.0-85142534780
https://hdl.handle.net/20.500.12105/23376
887056600001
Background: Transformation of follicular lymphoma into an aggressive lymphoma (tFL) worsens the prognosis and the standard treatment is not completely defined. Allogeneic hematopoietic stem cell transplantation (alloSCT) could be a potentially curative option for these patients, but it has not been widely explored. Methods: We designed a retrospective multicenter study to analyze the efficacy and toxicity of alloSCT in tFL patients and potential prognostic factors of survival. Results: A total of 43 patients diagnosed with tFL who underwent alloSCT in 14 Spanish centers between January 2000 and January 2019 were included. Median age was 44 (31-67) years. After a median follow-up of 58 months, estimated 5-year overall survival (OS) and progression-free survival (PFS) were both 35%. Estimated 100-day and 1-year non-relapse mortality (NRM) were 20% and 34%, respectively. The type of conditioning regimen (3-year OS of 52% vs. 20%, respectively, for reduced-intensity vs. myeloablative conditioning) and development of chronic graft versus host disease (cGVHD) (3-year OS of 75% vs. 40%) were the only factors significantly associated with OS. The only variable with an independent association with OS was cGVHD (HR, 3.4; 95% CI, 1.2-9.6). Conclusions: Our results indicate that alloSCT continues to be a potentially curative option for patients with tFL.
eng
Allogeneic Hematopoietic Stem Cell Transplantation in Transformed Follicular Lymphoma (tFL): Results of a Retrospective Multicenter Study from GELTAMO/GETH-TC Spanish Groups
research article